| Zacks Company Profile for Aclaris Therapeutics, Inc. (ACRS : NSDQ) |
|
|
| |
| • Company Description |
| Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.
Number of Employees: 64 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $1.59 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,240,483 shares |
| Shares Outstanding: 108.28 (millions) |
| Market Capitalization: $172.17 (millions) |
| Beta: 0.38 |
| 52 Week High: $5.17 |
| 52 Week Low: $1.05 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
3.92% |
0.03% |
| 12 Week |
39.47% |
17.32% |
| Year To Date |
-35.89% |
-39.96% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Neal Walker - Chief Executive Officer; and Chairman of the Board
Hugh Davis - President; Chief Operating Officer
Kevin Balthaser - Chief Financial Officer
Maxine Gowen - Director
Vincent Milano - Director
|
|
Peer Information
Aclaris Therapeutics, Inc. (GSAC)
Aclaris Therapeutics, Inc. (CASI)
Aclaris Therapeutics, Inc. (ALCD.)
Aclaris Therapeutics, Inc. (OMNN)
Aclaris Therapeutics, Inc. (CGPI.)
Aclaris Therapeutics, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 00461U105
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
|
|
Share - Related Items
Shares Outstanding: 108.28
Most Recent Split Date: (:1)
Beta: 0.38
Market Capitalization: $172.17 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.14 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.55 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 5.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/06/25 |
|
|
|
| |
